The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines.
Two human small cell lung cancer (SCLC) cell lines were used to evaluate the in vitro response to lonidamine and cisplatin exposure. The two cell lines both showed growth inhibition when exposed to lonidamine alone at concentrations greater than 50 micrograms/ml; however, one cell line (H69) was more sensitive. When cisplatin was combined with lonidamine a synergistic interaction was observed when cells were exposed to 10 microM cisplatin for 1 hour combined with lonidamine at concentrations of 50 micrograms/ml or greater. At a concentration of 25 micrograms/ml lonidamine combined exposure with cisplatin had no effect on cell growth or viability.
Ko
D
D
Ottawa Regional Cancer Centre, Ontario, Canada.
Raaphorst
G P
GP
Feeley
M M
MM
Danjoux
C E
CE
Maroun
J A
JA
Evans
W K
WK
D000970:Antineoplastic Agents / Q000494:pharmacology*; D018288:Carcinoma, Small Cell; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004347:Drug Interactions; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007191:Indazoles / Q000494:pharmacology*; D007700:Kinetics; D008175:Lung Neoplasms
D000970:Antineoplastic Agents; D007191:Indazoles; D002945:Cisplatin; C016371:lonidamine